9,370 Shares of Invesco Biotechnology & Genome ETF $PBE Purchased by Newman Dignan & Sheerar Inc.

Newman Dignan & Sheerar Inc. bought a new position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,370 shares of the company’s stock, valued at approximately $912,000. Newman Dignan & Sheerar Inc. owned about 0.22% of Invesco Biotechnology & Genome ETF at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Compass Financial Management LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the second quarter valued at $27,000. Fifth Third Bancorp purchased a new stake in Invesco Biotechnology & Genome ETF during the 1st quarter valued at about $30,000. Integrated Wealth Concepts LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the 2nd quarter valued at about $84,000. Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the 3rd quarter valued at about $204,000. Finally, MinichMacGregor Wealth Management LLC acquired a new position in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $372,000.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of PBE stock opened at $99.22 on Wednesday. Invesco Biotechnology & Genome ETF has a fifty-two week low of $72.27 and a fifty-two week high of $99.75. The firm has a market capitalization of $430.61 million, a PE ratio of 20.44 and a beta of 0.70. The stock’s 50-day simple moving average is $96.17 and its 200-day simple moving average is $89.13.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.